Herpes zoster
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Herpes zoster blisters li ser stû û mil
relevance score : -100.0%
ReferencesŞengal, ku ji nû ve aktîvkirina vîrusa varicella zosterê e, pêk tê; her sal li dora 1 mîlyon mirov li Dewletên Yekbûyî tê dîtin, û xetereya jiyanê 30 % e. Kesên ku pergalên berevaniyê yên qels hene, bi girîngî meyla pêşkeftina şengalê zêde dikin. Nîşanên sereke di nav dema xuyangkirina rashê de, wekî serêş, tayek sivik û hestên çermê neasayî, çend roj berî rashê xuya dibin. Rijandîn bi gelemperî li deverek taybetî ya laş xuya dibe; di hefteyekê de rashê bi bilbilên zelal dest pê dike û di dema 10 rojan de bi birînên pelçiqandî berdewam dibe. Dermankirina bilez bi dermanên antîviral (acyclovir, valacyclovir, famciclovir) di nav 72 demjimêr de piştî destpêkirina rashê pir girîng e. Neuralgiya postherpetîk, ku êşê dirêjkirî li devera bandorkirî tê deyar kirin, li ser yek ji pênc nexweşan bandor dike. Ji bo birêvebirina domdar, dermanên wekî gabapentin, pregabalin, an hin antîdepresan, û ajanên herêmî yên wekî lidocaine an capsaicin pêwîst in. Vaksîna li dijî vîrusa varicella zoster ji bo kesên 50 salî û jortir pêşniyar dibe da ku xetera zosterê kêm bike.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster di mirovên 50 salî û mezintir de, yên ku pergalên xweparastinê qels in û yên ku dermanên immunosuppressant digirin, pir caran çêdibe. Ew ji nû ve aktîvkirina vîrusa varicella‑zoster, heman vîrusê ku sedema mirina mirîşkan dibe, çêdibe. Nîşanên wekî tayê, êş û xurînê bi gelemperî pêşî li xuyangkirina tîrêjê ya taybetmendiyê xuya dibin. Herî berbelav tevlihevî neuralgiya post‑herpetîk e, ku êşa domdar a nervê piştî ku rash paqij dibe. Faktorên xetereyê û tevliheviyên ku bi herpes zoster re têkildar in, li gorî temen, rewşa tenduristiyê û dema destpêkirina dermankirinê diguhere. Derzîlêdana ji bo kesên 60 salî û jortir hate destnîşan kirin, ku bi girîngî rûdana herpes zoster û neuralgiya post‑herpetîk kêm dike. Destpêkirina dermanên antîviral û dermanên êşê di nav 72 demjimêran de, piştî destpêkirina rashê, dikare giranî û tevliheviyên herpes zoster û neuralgiya post‑herpetîk kêm bike.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Lêkolînên klinîkî yên berî pejirandinê nîşan dide ku vakslêdana zostera zindî li dora 50–70% dixebite, dema ku vakslêdana rekombînant çêtir dike, ji 90 heta 97%. Di lêkolînên cîhanê rastîn de, ew piştgirî dikin encamên ceribandinê, û nîşan dide ku vakslêdana zindî bi qasî 46% bandor e, dema ku ya rekombînant li dora 85%.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Ger birîn bi lez belav dibin, ji bo dermankirina antîvîrusê di zûtirîn dem de doktorê xwe bibînin. Hem dermanên antiviral hem jî dermanên neuralgiyê hewce ne. Divê hûn bêhna xwe bidin û dev ji vexwarina alkolê berdin.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin